Cephea Valve Technologies

Cephea Valve Technologies is the American company which is engaged in development of low-invasive technologies of prosthetics of the mitralny valve at patients with the purchased heart diseases. The headquarters of the company is in Santa Clara, the State of California.

History

2019: Abbott purchased Cephea

On January 16, 2019 the large producer of the medical equipment of Abbott Laboratories announced acquisition of the Cephea Valve Technologies company developing technologies of replacement of the mitralny valve. Transaction amount of the party decided not to open.

In July, 2015 Abbott provided to Cephea Valve Technologies financial resources and then agreed about a possibility of a company takeover in the future. Then Abbott purchased not only the purchase option Cephea Valve Technologies, but also Tendyne Holdings company which is engaged in development of minimum and invasive products for complete replacement of the mitralny valve.

Abbott is engaged in development of minimum invasive solutions for patients with a disease of the mitralny valve since 2009 when it purchased Evalve company and its MitraClip technology. This development is considered the first in the class product for normalization of operation of the damaged valves.

Abbott purchased the developer of low-invasive technologies of replacement of the mitralny valve

According to representatives of Abbott, Cephea develops technology of replacement of the mitralny valve at which all tools and materials will be delivered through a venous system, eliminating with that need for transaction on open heart. New approach of Cephea on replacement of the mitralny valve supplements a portfolio of minimum invasive Abbott technologies based on use of venous catheters, the vice president for sale of products for treatment of structural diseases of heart Michael Dale explained. By the beginning of 2019 it is predicted that in the years ahead the size of the market of similar low-invasive solutions will reach several billion dollars.^[1]

Notes